Market Overview:
The global teicoplanin market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of hospital-acquired infections (HAIs) and rising demand for teicoplanin as a result. Teicoplanin is an antibiotic that is used in the treatment of various types of infections, including those caused by MRSA (methicillin-resistant Staphylococcus aureus). It is available in two formulations – 200 mg and 400 mg – and can be administered orally or intravenously. The global teicoplanin market has been segmented on the basis of type, application, and region. On the basis of type, it has been segmented into 200 mg and 400 mg formulations. On the basis of application, it has been segmented into adults and children. Geographically, it has been segmented into North America, Latin America, Europe Asia Pacific ,and Middle East & Africa .
Product Definition:
A glycopeptide antibiotic used to treat serious infections, often caused by multi-resistant bacteria. Teicoplanin is administered intravenously and is effective against a range of Gram-positive bacteria, including MRSA (methicillin-resistant Staphylococcus aureus).
200 mg:
200 mg of Teicoplanin is used for the treatment of acute bacterial skin and soft tissue infections. It works by killing the bacteria that causes infection. The drug has a wide range of applications, including pneumonia, pyelonephritis, and urinary tract infections. 200 mg tablets are white in color with an imprinted score line on one side and 100 on the other side.
400 mg:
400 mg of Teicoplanin is used in the treatment of complicated skin infections such as impetigo, furunculosis, and necrotizing infections. 400 mg tablets are usually prescribed for patients who have not responded to 200 mg tablets.
Application Insights:
The adults segment held the largest share of over 70.0% in 2017. Rising awareness regarding various health issues among adults coupled with growing Teicoplanin intake for the treatment of acute respiratory distress syndrome (ARDS) is expected to drive product demand in this segment over the forecast period. In addition, high adoption rates for cost-effective healthcare and increasing disposable income levels are further anticipated to propel market growth during the study period.
The children application segment is expected to witness significant growth owing to rising prevalence of asthma and other lung diseases such as cystic fibrosis and bronchiectasis among children across regions including North America, Europe, Asia Pacific.
Regional Analysis:
Europe dominated the global market in terms of revenue share in 2017. The presence of key manufacturers and suppliers, coupled with high healthcare expenditure, is expected to drive the regional market over the forecast period. Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising product demand as a generic drug and increasing geriatric population prone to infections. In addition, growing awareness regarding chronic wound management using teicoplanin-based products is likely to propel regional growth.
The U.S., which was at forefront of innovation for introducing first ever generic version of vancomycin (teicoplanin), has witnessed a steep decline in its use since 2014 dueSto an increase in incidence rates for Clostridium difficile infection (CDI).
Growth Factors:
- Increasing incidence of hospital acquired infections (HAIs) due to multi-drug resistant pathogens is expected to drive the demand for teicoplanin over the forecast period.
- Rising geriatric population base is also anticipated to fuel the growth of this market as elderly are more susceptible to HAIs.
- Growing number of surgical procedures and rising prevalence of chronic diseases are also expected to boost the demand for teicoplanin in coming years.
- Technological advancements in drug discovery and development processes are likely to provide lucrative opportunities for players operating in this market over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Teicoplanin Market Research Report
By Type
200 mg, 400 mg
By Application
Adults, Children
By Companies
Sanofi, Labatec-Pharma SA, Cipla, Zhejiang Medicine Co. Ltd., ZHEJIANG HISUN PHARMACEUTICAL, North China Pharmaceutical Group Corporation
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
238
Number of Tables & Figures
167
Customization Available
Yes, the report can be customized as per your need.
Global Teicoplanin Market Report Segments:
The global Teicoplanin market is segmented on the basis of:
Types
200 mg, 400 mg
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Adults, Children
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi
- Labatec-Pharma SA
- Cipla
- Zhejiang Medicine Co. Ltd.
- ZHEJIANG HISUN PHARMACEUTICAL
- North China Pharmaceutical Group Corporation
Highlights of The Teicoplanin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 200 mg
- 400 mg
- By Application:
- Adults
- Children
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Teicoplanin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Teicoplanin is a drug used to treat severe pneumonia. It works by stopping the growth of bacteria in the lungs.
Some of the major companies in the teicoplanin market are Sanofi, Labatec-Pharma SA, Cipla, Zhejiang Medicine Co. Ltd., ZHEJIANG HISUN PHARMACEUTICAL, North China Pharmaceutical Group Corporation.
The teicoplanin market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Teicoplanin Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Teicoplanin Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Teicoplanin Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Teicoplanin Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Teicoplanin Market Size & Forecast, 2018-2028
4.5.1 Teicoplanin Market Size and Y-o-Y Growth
4.5.2 Teicoplanin Market Absolute $ Opportunity
Chapter 5 Global Teicoplanin Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Teicoplanin Market Size Forecast by Type
5.2.1 200 mg
5.2.2 400 mg
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Teicoplanin Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Teicoplanin Market Size Forecast by Applications
6.2.1 Adults
6.2.2 Children
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Teicoplanin Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Teicoplanin Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Teicoplanin Analysis and Forecast
9.1 Introduction
9.2 North America Teicoplanin Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Teicoplanin Market Size Forecast by Type
9.6.1 200 mg
9.6.2 400 mg
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Teicoplanin Market Size Forecast by Applications
9.10.1 Adults
9.10.2 Children
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Teicoplanin Analysis and Forecast
10.1 Introduction
10.2 Europe Teicoplanin Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Teicoplanin Market Size Forecast by Type
10.6.1 200 mg
10.6.2 400 mg
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Teicoplanin Market Size Forecast by Applications
10.10.1 Adults
10.10.2 Children
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Teicoplanin Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Teicoplanin Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Teicoplanin Market Size Forecast by Type
11.6.1 200 mg
11.6.2 400 mg
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Teicoplanin Market Size Forecast by Applications
11.10.1 Adults
11.10.2 Children
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Teicoplanin Analysis and Forecast
12.1 Introduction
12.2 Latin America Teicoplanin Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Teicoplanin Market Size Forecast by Type
12.6.1 200 mg
12.6.2 400 mg
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Teicoplanin Market Size Forecast by Applications
12.10.1 Adults
12.10.2 Children
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Teicoplanin Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Teicoplanin Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Teicoplanin Market Size Forecast by Type
13.6.1 200 mg
13.6.2 400 mg
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Teicoplanin Market Size Forecast by Applications
13.10.1 Adults
13.10.2 Children
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Teicoplanin Market: Competitive Dashboard
14.2 Global Teicoplanin Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sanofi
14.3.2 Labatec-Pharma SA
14.3.3 Cipla
14.3.4 Zhejiang Medicine Co. Ltd.
14.3.5 ZHEJIANG HISUN PHARMACEUTICAL
14.3.6 North China Pharmaceutical Group Corporation
